Nicolas Naclerio becomes chief business officer at Hayward, Calif.-based protein chip maker Zyomyx. His last post was at Motorola, where he founded the company’s life sciences division.
Hugues Sicotte and Peder Thusgaard Ruhoff climb aboard MDS Proteomics as directors for the Toronto company’s informatics team. Sicotte, who will be responsible for developing the bioinformatics and supercomputing software platform, was a staff scientist at NCBI.
Cynthia French, former president of Diogenics, heads to Pluvita as senior VP of R&D after the company acquired a majority stake in Diogenics. French has previously worked with DuPont and BioRad, among others.
Burt Adelman of Biogen was promoted from vice president of medical research to executive vice president of research and development. Adelman, who has been with Biogen since 1991, also lectures in medicine at Harvard Med.
Third Wave Technologies found its CFO in John Puisis, who comes from Kraft Foods, where he was executive director of finance and strategy. He has also worked for executive recruitment firms, where he specialized in biotechnology.
Aptus Genomics, which works primarily with GPCR genes, names as president Krystyna Belendiuk, who co-founded Pharmavene — now Shire Labs.
Formerly with Isotope Products Laboratories, Leonard Hendrickson replaces interim head James Chamberlain as president and CEO at BioSource International, a functional genomics company in Camarillo, Calif.
NCI director Richard Klausner left to be president of the new Case Institute of Health, Science, and Technology. He’s known for doubling NCI’s budget during his tenure and for organizing the agency’s subscription deal with Celera Genomics announced earlier this year.
Helicon Therapeutics, a functional genomics firm focusing on memory formation, chose John Tallman for its president and CEO. Tallman heads to the New York company from Neurogen, where he was CSO.
CombiMatrix, a subsidiary of Acacia Research, appoints Amit Kumar to its CEO slot. Kumar, who comes directly from Acacia, previously worked at genomic and proteomic tool firm Signature Bioscience.
Charles Hamner, 66, will retire from president and CEO of the North Carolina Biotechnology Center March of next year. Hamner, who joined the center in 1988, is credited with leading North Carolina’s drive into the biotech sector, which includes funding and recruiting almost 70 companies and starting the state’s Genomics and Bioinformatics Consortium.